Patents by Inventor Peter Ordentlich

Peter Ordentlich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20260151395
    Abstract: The present invention is directed to combinations of menin inhibitors with one or more CYP3A4 inhibitors, pharmaceutical compositions thereof, and methods of treating cancer and other diseases mediated by the menin-MLL interaction. Accordingly, the present disclosure provides compounds, e.g., of Formula (II), which inhibit menin and are useful in the treatment of diseases mediated by the menin-MLL interaction in combination with a strong CYP3A4 inhibitor.
    Type: Application
    Filed: January 23, 2026
    Publication date: June 4, 2026
    Inventors: Gerard M. MCGEEHAN, Peter ORDENTLICH, Galit ROSEN, Steven A. SMITH
  • CSF-1R ANTIBODIES FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
    Publication number: 20260132210
    Abstract: The present invention relates to methods of treating sclerotic conditions and more specifically to methods of treating chronic graft versus host disease with specific dosages of an anti-CSF-1R antibody, specifically axatilimab.
    Type: Application
    Filed: January 13, 2026
    Publication date: May 14, 2026
    Inventors: Peter ORDENTLICH, Michael MEYERS, Briggs W. MORRISON
  • Combinations of menin inhibitors and CYP3A4 inhibitors and methods of use thereof
    Patent number: 12564590
    Abstract: The present invention is directed to combinations of menin inhibitors with one or more CYP3A4 inhibitors, pharmaceutical compositions thereof, and methods of treating cancer and other diseases mediated by the menin-HLL interaction. Accordingly, the present disclosure provides compounds, e.g., of Formula (II), which inhibit menin and are useful in the treatment of diseases mediated by the menin-MLL interaction in combination with a strong CYP3A4 inhibitor.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: March 3, 2026
    Assignee: Syndax Pharmaceuticals, Inc.
    Inventors: Gerard M. McGeehan, Peter Ordentlich, Galit Rosen, Steven A. Smith
  • CSF-1R antibodies for the treatment of chronic graft versus host disease
    Patent number: 12552869
    Abstract: The present invention relates to methods of treating sclerotic conditions and more specifically to methods of treating chronic graft versus host disease with specific dosages of an anti-CSF-1R antibody, specifically axatilimab.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: February 17, 2026
    Assignee: Syndax Pharmaceuticals, Inc.
    Inventors: Peter Ordentlich, Michael Meyers, Briggs W. Morrison
  • METHOD OF TREATING CANCER USING A COMBINATION OF ENTINOSTAT AND AN ANTI-CSF-1R ANTIBODY
    Publication number: 20250064925
    Abstract: The present disclosure relates to a combination of an anti-CSF-1R antibody or anti-CSF-1 antibody or antigen binding fragment thereof or an inhibitor of CSF-1R activity and an HDAC inhibitor, e.g., entinostat, and methods of using the combination for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: November 14, 2024
    Publication date: February 27, 2025
    Inventors: Peter ORDENTLICH, Lei WANG
  • METHODS OF TREATING CHRONIC GRAFT-VERSUS-HOST DISEASE-RELATED BRONCHIOLITIS OBLITERANS SYNDROME USING AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY
    Publication number: 20250011441
    Abstract: The present disclosure provides methods of treating chronic graft-versus-host disease (cGVHD)-related bronchiolitis obliterans syndrome using an antibody that binds to colony stimulating factor 1 receptor (CSF-1R).
    Type: Application
    Filed: May 16, 2024
    Publication date: January 9, 2025
    Inventors: Peter Ordentlich, Vedran Radojcic
  • Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
    Patent number: 12168054
    Abstract: The present disclosure relates to a combination of an anti-CSF-1R antibody or anti-CSF-1 antibody or antigen binding fragment thereof or an inhibitor of CSF-1R activity and an HDAC inhibitor, e.g., entinostat, and methods of using the combination for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: December 17, 2024
    Assignee: Syndax Pharmaceuticals, Inc.
    Inventors: Peter Ordentlich, Lei Wang
  • COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER
    Publication number: 20240398944
    Abstract: Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.
    Type: Application
    Filed: August 8, 2024
    Publication date: December 5, 2024
    Inventors: Robert GOODENOW, Peter ORDENTLICH
  • SELECTION OF PATIENTS FOR COMBINATION THERAPY
    Publication number: 20240288425
    Abstract: Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising an HDAC inhibitor and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type which are CD14-positive, HLA-DR-high and/or CD16-negative, as a therapeutic indicator in the setting of HDAC inhibitor combination therapies.
    Type: Application
    Filed: April 29, 2024
    Publication date: August 29, 2024
    Inventors: Peter ORDENTLICH, Lei WANG, Serap SANKOH, Michael MEYERS
  • COMBINATIONS FOR TREATMENT OF CANCER
    Publication number: 20240238291
    Abstract: The present disclosure is directed to combinations of menin inhibitors and Bcl-2 inhibitors, optionally in further combination with hypomethylating agents and/or FLT3 inhibitors for the treatment of cancer. Specifically, menin inhibitors combined with venetoclax are synergistic in the treatment of cancers with a HOX gene signature such as acute myeloid leukemia.
    Type: Application
    Filed: May 12, 2022
    Publication date: July 18, 2024
    Inventors: Gerald M. MCGEEHAN, Peter ORDENTLICH, Bing CARTER, Michael ANDREEFF
  • Selection of patients for combination therapy
    Patent number: 12000829
    Abstract: Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising an HDAC inhibitor and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type which are CD14-positive, HLA-DR-high and/or CD16-negative, as a therapeutic indicator in the setting of HDAC inhibitor combination therapies.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: June 4, 2024
    Assignee: Syndax Pharmaceuticals, Inc.
    Inventors: Peter Ordentlich, Lei Wang, Serap Sankoh, Michael Meyers
  • COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230165858
    Abstract: The present invention is directed to combinations of menin inhibitors with one or more CYP3A4 inhibitors, pharmaceutical compositions thereof, and methods of treating cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: April 7, 2021
    Publication date: June 1, 2023
    Inventors: Gerard M. MCGEEHAN, Peter ORDENTLICH, Galit ROSEN, Steven A. SMITH
  • SELECTION OF PATIENTS FOR COMBINATION THERAPY
    Publication number: 20230061048
    Abstract: Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.
    Type: Application
    Filed: March 29, 2022
    Publication date: March 2, 2023
    Applicant: Syndax Pharmaceuticals, Inc.
    Inventor: Peter ORDENTLICH
  • ANTIBODIES FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
    Publication number: 20230035183
    Abstract: The present invention relates to methods of treating sclerotic conditions and more specifically to methods of treating chronic graft versus host disease with specific dosages of an anti-CSF-1R antibody, specifically axatilimab.
    Type: Application
    Filed: December 9, 2020
    Publication date: February 2, 2023
    Inventors: Peter ORDENTLICH, Michael MEYERS, Briggs W. MORRISON
  • COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER
    Publication number: 20230022573
    Abstract: Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.
    Type: Application
    Filed: April 8, 2022
    Publication date: January 26, 2023
    Applicant: Syndax Pharmaceuticals, Inc.
    Inventors: Robert GOODENOW, Peter ORDENTLICH
  • Selection of patients for combination therapy
    Patent number: 11397184
    Abstract: Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: July 26, 2022
    Assignee: SYNDAX PHARMACEUTICALS, INC.
    Inventor: Peter Ordentlich
  • Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
    Patent number: 11324822
    Abstract: Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 10, 2022
    Assignee: Syndax Pharmaceuticals, Inc.
    Inventors: Robert Goodenow, Peter Ordentlich
  • SELECTION OF PATIENTS FOR COMBINATION THERAPY
    Publication number: 20210239697
    Abstract: Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising an HDAC inhibitor and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type which are CD14-positive, HLA-DR-high and/or CD16-negative, as a therapeutic indicator in the setting of HDAC inhibitor combination therapies.
    Type: Application
    Filed: May 7, 2019
    Publication date: August 5, 2021
    Inventors: Peter ORDENTLICH, Lei WANG, Serap SANKOH, Michael MEYERS
  • COMBINATION THERAPIES
    Publication number: 20200171150
    Abstract: The present disclosure relates to a combination of an anti-CSF-1R antibody or anti-CSF-1 antibody or antigen binding fragment thereof or an inhibitor of CSF-1R activity and an HDAC inhibitor, e.g., entinostat, and methods of using the combination for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: May 18, 2018
    Publication date: June 4, 2020
    Inventors: Peter ORDENTLICH, Lei WANG
  • METHODS FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20190343844
    Abstract: Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
    Type: Application
    Filed: January 15, 2019
    Publication date: November 14, 2019
    Inventors: Robert GOODENOW, Peter ORDENTLICH